

EuroGCT, D2-2: Research community hub, a report on dissemination and uptake of information produced in WP4 via the EuroGCT online research and regulatory community hub

Aurélie Mahalatchimy, Auxane Delage, Luc-Sylvain Gilbert, Hsin-Yu Kuo, Anna Couturier, Jennifer Lorigan, Clare Blackburn

▶ To cite this version:

Aurélie Mahalatchimy, Auxane Delage, Luc-Sylvain Gilbert, Hsin-Yu Kuo, Anna Couturier, et al.. EuroGCT, D2-2: Research community hub, a report on dissemination and uptake of information produced in WP4 via the EuroGCT online research and regulatory community hub. European Commission - CORDIS. 2023, https://cordis.europa.eu/project/id/965241/results. halshs-04290634

HAL Id: halshs-04290634 https://shs.hal.science/halshs-04290634

Submitted on 16 Nov 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Deliverable Report

Grant Agreement Number: 965241

Project acronym: EuroGCT

Project title: European Consortium for Communicating Gene and Cell Therapy Information

Deliverable: D2.2 Research community hub

Report on dissemination and uptake of information produced in WP4 via the EuroGCT online research and regulatory community hub

Date: 31st July 2023



Project	
Project acronym:	EuroGCT
Project full title:	European Consortium for Communicating Gene and Cell Therapy Information
Grant agreement no .:	965241
Funding scheme:	Co-ordination and Support Action
Project start date:	1 February 2021
Project duration:	60 months
Call topic:	SC1-HCO-19-2020 - Reliable and accessible information on cell and gene-based therapies
Project website:	www.eurogct.org
Document	
Deliverable number:	D2.2
Deliverable title:	Research community hub, a report on dissemination and uptake of information produced in WP4 via the EuroGCT online research and regulatory community hub
Due date of deliverable:	Month 30
Associated Milestones	NA
Actual submission date:	28 July 2023
Last Editor:	Hsin-Yu Kuo
Contributors:	Aurélie Mahalachimy, Auxane Delage, Luc-Sylvain Gilbert, Hsin-Yu Kuo, Anna Couturier, Jennifer Lorigan, Clare Blackburn
Work Package no.:	2
Work Package title:	Digital Platforms for Dissemination and Engagement
Work Package lead beneficiary:	1-UEDIN
Work Package participants:	1-UEDIN, 2-AMU, 3-Fraunhofer
Dissemination level:	Public
Nature:	Report
Draft/Final:	Final
No of pages (including cover):	16 (Main report) + 11 (Annex)



Table of Contents

De	livera	ble Report	1
Lis	t of ac	cronyms	4
		port on dissemination and uptake of information produced in WP4 via the T online research and regulatory community hub	5
		ablishment and updating of the Research Pathways Hub, an interactive	5
2.	Sum	nmary of Dissemination Activities	6
2	2.1	Events	6
2	2.2	List of oral communications and posters	7
2	2.3	Additional events	9
3.	Upta	ake	10
3	3.1	Collaboration formed and/or currently in discussion	10
3	3.2	Collaboration inquiries received	11
3	3.3	Website traffic	11
4.	Con	clusion and future work	16
5.	List	of Annexes	16



List of acronyms

ATMP: Advanced Therapy Medicinal Products

EuroGCT: The European Consortium for Communicating Gene and Cell Therapy Information

IMHT: The EuroGCT Information Management Hub Team, comprised of project staff employed directly by the project, based at the University of Edinburgh (UEDIN) and Aix-Marseille University (AMU)

WP: Work Package



D2.2 Report on dissemination and uptake of information produced in WP4 via the EuroGCT online research and regulatory community hub

EuroGCT WP4 develops an information hub for the research and regulatory communities that facilitates access of these communities to information on the practical steps needed for cell and gene-based therapy development and promotes information exchange within and between these communities. This tailored section of <u>www.eurogct.org</u> aims to create a 'one-stop shop' on where to seek further information and guidance relating to manufacturing guidelines, regulatory requirements, intellectual property rights, market acceptability and ethical matters related to advanced therapies development.

Report D2.2 summarises the activities performed regarding the dissemination and uptake of information produced in WP4 between month 12 (since the launch of the new website) and month 30.

1. Establishment and updating of the Research Pathways Hub, an interactive database

The EuroGCT online research and regulatory community hub, named 'Research Pathways', contains a set of information resources on the practical steps needed for cell and gene therapy development. This resource set can be viewed online at <u>www.eurogct.org/research-pathways</u>, and is outlined in Deliverable 4.2 - Resources on practical steps, and detailed in D4.1 - Landscape mapping.

The Research Pathways hub contains information on practical steps needed for cell and gene therapy development, and includes information resources developed by the EuroGCT consortium plus signposting to external information resources. The current database is built on the initial information published by this project (see deliverable D4.9), new content developed by EuroGCT during the current reporting period, and signposting to additional collated resources. Content within Research Pathways will be continuously updated throughout the project duration.

In the last reporting period, the EuroGCT IMHT carried out a review of user experience of the Research Pathways Hub. Based on the outcome of the review, in months 18-30 we have updated the section's design from a hierarchical structure to a database model, which gives improved searchability and usability. The improvement is further enhanced by carefully designed taxonomies used for tagging, new search and filter functions, which also link to grouped topical sections outlined as follows:

- **Key Research Pathways**: this section contains the collection of resources developed by EuroGCT WP4.
- **Key Pathway Resources**: this section contains collated key resources on ATMP development by medicines agencies, and existing complementary work produced by other organisations.
- **Case Studies**: this new section contains case studies on ATMP development, and provides storylines for readers to walk through the resources in the Research Pathways database.
- **Patient and Public Involvement**: this links to the ATMP Engage Patient and Public Involvement (PPI) Directory, a searchable and filterable directory with PPI resources for developers of cell and gene therapies.



• Actors and Networks: this section contains our initial mapping of stakeholders in ATMP development in Europe and beyond.

Users can freely interact with the database by choosing to narrow down their searches with keywords or filters. They can also utilise the Research Pathway as a gateway to the topic-based sections and to look for resources within. We anticipate the improved searchability and usability resulting from the above work will greatly enhance the user's experience in search and navigation within the section, and in turn will improve engagement.

2. Summary of Dissemination Activities

Besides establishing the EuroGCT website and the 'Research Pathways' section within it, the EuroGCT Consortium has actively disseminated outputs of the project via event attendance, presentations (online and in-person), posters, and networking activities.

Because the content in the Research Pathways section is tailored toward experts, we have not prioritised dissemination through social media channels in WP4. Instead, we have focused on reaching WP4 target audiences directly in meetings and networking events for dissemination and engagement activities. The activities performed between months 12 and 30 are summarised below:

2.1 Events

Table 1 lists all events EuroGCT has attended during this reporting period. Entries highlighted in blue are those at which we presented posters or gave an oral presentation. Entries highlighted in green are events hosted by EuroGCT/University of Edinburgh. Please see D2.2 Annex for the posters and abstracts submitted within this reporting period.

Date / Place	Host	Theme
28-29 July 2022, 2022 International Mammalian Synthetic Biology Workshop, Edinburgh, UK	American Institute of Chemical Engineers (AIChE)	Synthetic biology research, emphasizing both basic and applied science.
10 Oct 2022, Edinburgh, UK	University of Edinburgh	EuroGCT Sharing best practice workshop
11-14 October 2022, ESGCT 29 th Annual Congress, Edinburgh, UK	European Society of Gene and Cell Therapy in collaboration with British Society for Gene and Cell Therapy	Gene and Cell Therapy – oral presentation and poster presentations A EuroGCT kiosk: for in-person engagement with conference attendees, raising awareness about the project recruiting Network of Expertise members and translators.
31 October 2022, CGEM Away Day, Edinburgh, UK	Centre for Genomics and Experimental Medicine (CGEM), The University of Edinburgh	Recent advancements in gene therapy research
07-08 Nov 2022, London, UK	University College London	Regulatory Science for Advanced (Gene and Cell) Therapies short courses



9-12 November 2022, 15 th	European Public Health	Strengthening health systems:
European Public Health	Conference Foundation	improving population health and being
Conference, Berlin,		prepared for the unexpected
Germany		
13 December 2022,	European Commission	Biosimilar medicines: multistakeholder
Brussels, Belgium		event
25 January 2023, online	EU Health Governance Research	Webinar EU Pharmaceutical Activity:
20 bandary 2020, binnib	Network	Challenges arising from the
	Network	Pharmaceutical Strategy and Beyond
07 Ech 2022 Ediphurgh LIK	University of Edinburgh Centre for	CRM internal seminar
07 Feb 2023, Edinburgh, UK	University of Edinburgh Centre for	CRIVI Internal Seminar
	Regenerative Medicine (CRM)	
17-18 April 2023,	University of Edinburgh, ReNEW	Generative AI and Gene and Cell
Copenhagen, Denmark	and the University of Copenhagen	Therapy Information Workshop
13 April 2023, Marseille,	GT 3M (Maladies rares, Mutation,	Séminaire interdisciplinaire essais
France	Méditerranée)	
		cliniques
23-26 April 2023, Paris,	European Society for Blood and	Key issues relating to HSCT and
France, 49 th Annual Meeting	Marrow Transplantation	cellular therapy research
of the European Society for		
Blood and Marrow		
Transplantation		
27-28 April 2023, Langen,	DG-GT (Deutsche Gesellschaft	The Next Frontiers in ATMP
Germany	für Gentherapy) / Paul-Ehrlich-	Development
	Institut	
11 May 2023, Online event	TESaCo (technologies	Biotechnologies : quelle sagesse
	émergentes et sagesse collective)	collective ? CRISPR-Cas9 Genome
	emergentes et sugesse concerve)	Editing
22 May 2023, Online event	TESaCo (technologies	Biotechnologies: quelle sagesse
22 May 2025, Online event		
	émergentes et sagesse collective)	collective? Novel forms of life:
00.14 0000 "	705	organoids
26 May 2023, online	T2Evolve	ATBX Spotlight Sessions
31 May-3 June 2023, Paris,	International Society for Gene and	Celebrating the progress of Advanced
France, Annual meeting of	Cell Therapy	Therapies and building the Future
the International Society for	Och merapy	through translations
Gene and Cell Therapy		
7 June, 2023, Edinburgh,	Institute for Regeneration and	Catapult UK Edinburgh Launch
UK	Repair at University of Edinburgh	
	University of Edinburgh	Science Communication workshop for
14 June 2023, Edinburgh,	University of Edinburgh	Science Communication workshop for
UK		graduate students
14 June 2023, Compiègne,	ITEGOREC	Innovations technologiques et greffe
France		d'organes : enjeux réglementaires,
		éthiques et culturels (organoïdes)
23 June 2023	Faculty of Law- Maynooth, Ireland	Meeting of the OUP Online
		Encyclopaedia of European Union
		Law: Evolving EU health law following
		the Covid-19 pandemic
27 July-31 July 2023,	CIVIS Blended Intensive	The science, ethics and governance of
University of Tübingen,	Programme	human genome editing
Germany		
6-7 July 2023, Toulouse,	École d'été 2023 de la Chaire	Approches éthiques et juridiques de la
France	UNESCO Éthique, Science et	vérité en science
	Société	are those at which we presented posters

Table 1. List of EuroGCT attended events. Entries highlighted in **blue** are those at which we presented posters or gave an oral presentation. Entries highlighted in **green** are events hosted by EuroGCT/University of Edinburgh.

2.2 List of oral communications and posters

Event	Oral communication / Poster



2022 International Mammalian Synthetic Biology Workshop (mSBW), 28-29 July 2022, Edinburgh, UK	1 poster: C. Blackburn, J. Lorigan, A. Waite, A. Couturier, HY. Kuo, Communicating reliable and accessible information about gene and cell therapy
2022 EuroGCT Sharing best practice workshop, 10 Oct 2022, Edinburgh, UK	 2 Oral presentations: A. Waite and F. Willingham, Partnering with patients—Case study on ATMP Engage PPIE Working Group A. Waite and A. Couturier, Working together as the EuroGCT partnership
European Society for Gene & Cell Therapy Congress 2022, 11-14 October 2022, Edinburgh, UK	Oral presentation: Z. lvics, Advances in Sleeping Beauty transposon-based therapeutic cell engineering
	Oral presentation: A. Waite, A. Couturier, Public engagement and communicating about gene and cell therapy Introductory session
	1 poster: A. DELAGE, LS. GILBERT, HY. KUO, J. LORIGAN, C. BLACKBURN, A. COUTURIER, A. WAITE, A. MAHALATCHIMY, Bringing gene and cell therapies from lab to patients: the EuroGCT research pathways
15th European Public Health Conference, 9-12 November 2022, Berlin, Germany	Oral communication: A. MAHALATCHIMY, The pandemic Treaty from an EU law perspective, roundtable on "Access, equity and the relevance of the Pandemic Treaty: lessons from the COVID-19 response" organized by Elena PETELOS
EU Health Governance Research Network seminar series, Panel discussion / webinar on "EU Pharmaceutical Activity: Challenges Arising From The Pharmaceutical Strategy And Beyond", 25 January 2023, online	Oral communication: A. MAHALATCHIMY and E. GENNET, Towards an inclusive and equitable pharmaceutical strategy for the EU
University of Edinburgh Centre for Regenerative Medicine (CRM) internal seminar, 07 Feb 2023, Edinburgh, UK	Oral presentation: , J. Lorigan and HY. Kuo, Get involved in communicating about gene and cell therapy
Generative AI and Gene and Cell Therapy Information Workshop, 17 April 2023, Copenhagen, Denmark	Oral communication: A. Couturier, Roundtable on "New developments in online marketing & information search: how should the stem cell community respond?"
GT 3M- Séminaire "Essais cliniques" 13 April 2023 Marseille, France	Oral communication: A. MAHALATCHIMY, Les spécificités réglementaires des essais cliniques pour les médicaments innovants
European Society for Blood and Marrow Transplant 49th annual meeting, 23-26 April 2023, Paris, France	1 poster: A. DELAGE, LS. GILBERT, HY. KUO, J. LORIGAN, C. BLACKBURN, A. COUTURIER, A. WAITE, A. MAHALATCHIMY, Finding out the regulatory requirements for the development of Gene and Cell therapy products with the EuroGCT research pathways
German Society for Gene Therapy (DG-GT) and Paul-Ehrlich-Institut (PEI) Conference: "The next frontiers in ATMP development", 27-28 April 2023, Langen, Germany	Oral presentation: A. Couturier, The EuroGCT Consortium: Meeting the information needs of all stakeholders in cell and gene therapy
TESaCo Colloquium on "Biotechnologies: towards collective wisdom", "New forms of life: how should organoids be regulated?", 22nd May 2023, online T2Evolve ATBX Spotlight Sessions 26 May 2023, online	Oral communication: A. MAHALATCHIMY, Challenges for the implementation of the current EU legal frameworks to organoids Oral presentation: J. Lorigan, The EuroGCT Consortium: sharing reliable information about cell
	and gene therapy



International Society for Cell & Gene Therapy, 2023 Paris Annual Meeting, 31 May - 3 June 2023, Paris, France	 2 oral communications: A. MAHALATCHIMY, Roundtable on "Regulatory Revolution: Global Harmonization for Safe Personalized Medicines" A. MAHALATCHIMY, Roundtable on "COVID-19 Hangover: How do we Regain the Trust in Research?"
	 2 posters: A. MAHALATCHIMY, LS. GILBERT, A. DELAGE, O. NEGRE, The Marketing Authorisation of Advanced Therapy Medicinal Products in the European Union A. MAHALATCHIMY, V. BRUNEL, Which actors to influence the adoption of EU guidelines for Advanced Therapy Medicinal Products?
Journée d'étude ITEGOREC- 14 June 2023 Compiègne, France	Oral communication: A. BOTTACCI et A. MAHALATCHIMY, Quel futur pour le cadre juridique des tissus et des organes destinés à la transplantation ? Le cas des organoïdes
University of Edinburgh Science Communication workshop for graduate students, 14 June 2023, Edinburgh, UK	Oral presentation: J. Lorigan EuroGCT: sharing reliable information about cell and gene therapy
EU Health Law Seminar "Evolving EU health law following the Covid-19 pandemic", Faculty of Law, 23 June 2023, Maynooth, Ireland	A. MAHALATCHIMY, Update on contributions on EU law on medicines (including on ATMPs)
CIVIS Blended Intensive Programme: The science, ethics, and governance of human genome editing, 27-31 July 2023, University of Tübingen, Germany	 3 lectures: A. MAHALATCHIMY, The fragmented regulatory landscape on human genome editing, Virtual Session 6, 5th July 2023 A. MAHALATCHIMY, Human genome editing for research & EU Law, 29 July 2023 A. MAHALATCHIMY, Human genome editing for therapy & EU Law, 29 July 2023

Table 2. List of EuroGCT oral presentations and posters.

2.3 Additional events

- Recurring online meetings:
 - International Society for Stem Cell Research (ISSCR) Education Committee (Dr. Anna Couturier, standing member)
 - EuroGCT Industry Working Group Meeting (Inaugural Meeting June 26, 2023)
 - ATMP Engage Working Group (co-led by NHS England and NHS Improvement and Genetic Alliance UK)
 - ATMP Engage Equity of Access working group meetings
 - Genetic Alliance UK ATMPs and Equity roundtable discussion
 - ESGCT-EuroGCT meetings for collaborating on EuroGCT programmes during 2023 ESGCT Congress
- EuroGCT partners meeting and Newsletter:
 - Online meetings held for Management group and General Committee according to grant agreement
 - Monthly newsletters for disseminating progresses made within the EuroGCT network



3. Uptake

The uptake of information produced in WP4 via the EuroGCT online research and regulatory community hub can be demonstrated by inquiries we received on collaborations, collaborations in discussion or formed, and website traffic stats.

3.1 Collaboration formed and/or currently in discussion:

- GetRadi The GetRadi collaboration is a Europe-wide project aimed at advancing gene therapy for rare diseases. With a focus on addressing technical challenges in the field, GetRadi trains 10 PhD students to become experts in gene therapy for rare diseases. EuroGCT, as a key partner in the collaboration, contributes by providing training in digital engagement to these students during the GetRadi Summer School. Additionally, EuroGCT serves as the platform for disseminating GetRadi digital engagement projects, fostering the development of impactful resources and also supporting young researchers.
- 2) ATMP Engage is a collaboration in which EuroGCT is a central partner. ATMP Engage brings together UK-based stakeholders with an interest in ATMPs to discuss and collaborate on Patient and Public Involvement (PPI) activity. The output of this collaboration is the "ATMP Engage PPI Directory" (www.eurogct.org/ppi-directory), a searchable and filterable directory with PPI resources for developers of cell and gene therapies, hosted on the EuroGCT website.
- 3) Established a collaboration with Canada and USA on legal aspects through the project "Law, Public Policy and Social License for Next-Generation Regenerative Medicine", funded by the Canadian Stem Cell Network (2022-2025) led by Prof Amy Zarzecny. A. Mahalatchimy is participating in this project as a EuroGCT partner and legal scholar.
- 4) Interest and inquiries received from Genetically Modified Organisms national authorities. Contacts with GMO national authorities were established, and this has resulted in a regulatory workshop 'GMO-based ATMPs' planned for the 2023 ESGCT Congress.
- 5) **CARTALLEU project**: A team at the Hospital Clinic Barcelona running a CAR-T therapy clinical trial have expressly requested to collaborate with us on co-developing educational resources about CAR-T clinical trials. In addition, their CAR-T product has been selected as the first of the five EMA pilot programme participants. Through this collaboration, we aim to co-develop learning resources for the researcher and developer community to learn and leverage from the team's experience in navigating the regulatory approval process in EU, and how they interact with regulators in EMA's pilot programme.
- T2Evolve: this project working on accelerating development and increasing awareness and access to cancer immunotherapy has reached out to us for collaborations.
- 7) Our relationship with The Committee for Advanced Therapies (CAT) at EMA has strengthened as a result of ESGCT 2022 and ISCT 2023 dissemination activities. EuroGCT is currently working on a proposal for a regulatory workshop at EMA in late 2024 with support from EMA/CAT.



- 8) Attracted one law assistant professor from the Netherlands to come for a 3months research stay at AMU to learn about ATMP regulations and to provide support on the organisation of a EuroGCT workshop at EMA.
- Contacts and proposals for collaborations with the Alliance for Regenerative Medicine (ARM) and the International Society for Cell & Gene Therapy (ISCT) established after poster presentations and roundtable discussions at ISCT 2023.
- Established an online collaboration: A. Mahalatchimy is working on an ATMP regulation entry for an online Encyclopaedia about "European Union Law" edited by Oxford University Press.
- 11) Received request to co-develop resources—an ATMP development Case Study on Libmeldy. EuroGCT WP4 is currently working together with Orchard Therapeutics on co-developing a case study an EMA-approved Gene therapy medicinal product (GTMP), Libmeldy, for the researcher and developer community to learn about its development process.
- 12) ISSCR Education Committee: EuroGCT has a long standing position on the ISSCR's Education Committee. This includes providing editorial oversight of the ISSCR Patient Handbook (A. Couturier, C. Blackburn). In November 2023, EuroGCT will run a communications seminar for all ISSCR members. Additionally, EuroGCT is planned to be involved in the public engagement and regulatory outreach for the ISSCR Annual Conference to be held in Hamburg, 2024.
- 13) ESGCT: EuroGCT has built collaborations with ESGCT to expand its support of European Gene and Cell Therapy researchers. This includes leading public engagement and regulatory support for the ESGCT Annual Congress – 2023 (Brussels) and collaborating with ESGCT on a heatmap of gene and cell therapy centres.

3.2 Collaboration inquiries received:

- 1) COST Action HaploiPS (Generation of Human Induced Pluripotent Stem Cells From Haplo-selected Cord Blood Samples)
- 2) Collaboration with the Human Gene Therapy Journal on providing lay abstract of key papers published in this journal

3.3 Website traffic

Complementary to direct engagement, the establishment of the EuroGCT online research and regulatory community hub, Research Pathways, broadens our dissemination actions and makes these outputs accessible to everyone, independent of their geographical location.

We note that the Research Pathways section produced by WP4 contains information that is mainly targeted toward experts and to a less extent, informed non-experts. The expert groups represent a small fraction of the total online population, and the likelihood of attracting online traffic that is at a comparable scale to our public-facing counterpart is low. Thus, reporting merely on the absolute visitor count is not suitable for evaluating the information uptake among these groups and the resulting impact. In this section, we



discuss and report the use of additional metrics to better assess our digital outreach, as well as information uptake by our target audience.

EuroGCT's effort on tracking webpage traffic is described in detail in D2.4. Briefly, we have made a conscious effort to focus on strict user privacy considerations, which results in challenges for reporting. For reporting uptake for WP4 content, we track passive user engagement using Fathom Analytics and Google Search Console. We will report webpage traffic using data drawn from Fathom Analytics; we will report on search rankings and top query terms using data drawn from Google Search Console. Based on Fathom Analytics, the top accessed WP4 pages and their unique visitor counts, and total views between website launch and 15 July 2023 are summarised in the Table 3 and ranked by total views:

Based on Fathom Analytics, the unique visitor counts and total views for the top accessed WP4 pages between website launch and 15 July 2023 are summarised in Table 3 and ranked by total views.

Webpage	Visitors	Total Views
eurogct.org/ (EuroGCT main landing page)	8.1k	11.5k
eurogct.org/research-pathways	1k	2.4k
eurogct.org/atmp-ppi-database	267	1.6k
eurogct.org/atmp-engage	666	1k
eurogct.org/ppi-directory	391	701
eurogct.org/key-pathway-resources	215	508
eurogct.org/research-pathways/research-and-	261	439
innovation		
eurogct.org/research-	316	401
pathways/manufacturing/manufacturing-authorisation		
eurogct.org/research-	248	298
pathways/manufacturing/packaging-and-labelling		

Table 3. Top accessed WP4 pages and their unique visitor counts, and total views between 1 Feb 2022 (website launch) and 15 July 2023

The entry highlighted in grey is the main EuroGCT landing page, included here for benchmarking purpose. The three entries highlighted in **blue** refer to the same suite of information, the ATMP Engage Public and Patient Involvement Directory. The two entries highlighted in green are EuroGCT original resource pages.

Below we report and discuss features and user characteristics captured for three major types of pages in the Research Pathways information hub: 1) directory search pages, 2) topical pages, and 3) individual resource page.

1) **Directory search pages**, including Research Pathways and ATMP Engage PPI Directory:

The pages containing directories received total views that are 2-6 times higher than their unique visitor number. This is distinct from the public-facing resource pages (WP3) where the views and unique visitor number are near 1:1 (see D2.4). This observation suggests that these directory pages have started to be used as a reference page for certain user groups as a standing resource for regular re-visit and to look up resources. This suggestion is further supported by Fathom Analytic's



referrer record for these WP4 pages being largely Direct/Unknown and not redirected from search engines (see Figure 1 and 2). A referrer is the site a visitor was previously on before they were redirected to our site. The EuroGCT site's average bounce rate, defined as the percentage of visitors who enter the site and then leave, is 74%. A significantly lower bounce rate (36% for 'Research Pathways' and 54% for 'ATMP Engage PPI Directory') is recorded for these directory search pages (see Figure 1 and 2). This translates to 64% and 46% of users respectively, who remain on our site and continue to browse content on our website after landing at this page.

EuroGCT •						Feb 1, 2022 to Jul 1	5, 2023 👔
Path is "/research-pathways'	* 🛞 Clear filters						
1 Filter applied	180 Visitors +171	2.4k • Views +2.2k		01:09 Avg time on site		O Event completions	
Domains Pages		Entries	Visitors	Views	Referrers Refs	Visitors	Views
eurogct.org/research-pathw	rays	180	1k	2.4k	Direct / Unknown	165	2.4k
					Twitter	6	6
					Google	4	5
					keep.google.com	3	4
					Baidu	1	1
					statics.teams.cdn.office.net	1	3
					Bing	0	3

Figure 1. Webpage stats for the 'Research Pathways' directory search page. Main referrers are not search engines. A low bounce rate (36%) is recorded. Reported from Fathom Analytics between website launch and 15 July 2023.

EuroGCT •							Feb 1, 2022 to Jul 1	5, 2023
th is "/atmp-ppi-databa 1 Filter applied	Se" Clear filters	1.6k • Views +1.6k		01:14 Avg time on site		54% • Bounce rate +54%	O Event completions	
Domains Pages		Entries	Visitors	Views	Referrers	Refs	Visitors	Views
eurogct.org/atmp-ppi-d	latabase	44	267	1.6k	Direct / Uni	known	33	1.5k
					Google		10	12
					statics.tear	ms.cdn.office.net	1	1

Figure 2. Webpage stats for the 'ATMP Engage PPI Directory' search page. Main referrers are not search engines. A low bounce rate (54%) is recorded. Reported from Fathom Analytics between website launch and 15 July 2023.

2) Topical pages:

Topical pages such as the 'Key Pathways Resources' page contain handpicked key resources on ATMP development and categorised by themes. For this type of page, the referrers are about 1:1 for search engines and Direct/unknown. A slightly lower bounce rate (62%) is recorded in Fathom Analytics (see Figure 3) indicating 38% of users remain on the site and continue to browse content.






Figure 3. Webpage stats for the 'Key Pathways Resources' topical page containing handpicked key resources on ATMP development. Referrers are about 1:1 for search engines and Direct/unknown. A lower bounce rate (62%) is recorded. Record in Fathom Analytics between website launch and 15 July 2023.

3) Individual resources, including in-house resources and external resources:

Resources including 'Packaging and labelling' and 'Manufacturing authorisation' developed by the EuroGCT consortium are mostly accessed through organic searches as shown in Fathom Analytics (see Figure 4 for the stats of the 'Manufacturing authorisation' page as an example).

These pages appear in top 20 search results in Google using relevant query terms, and more often, are ranked within top 5 using exact search terms. (see Figure 5 for the stats of the 'Manufacturing authorisation' page as an example). The click-through rate (CTR) for these top-ranked search results are also significantly higher. For the case of 'Manufacturing authorisation' page, the CTR can often reach 10% when similar query terms are used in searches (see Figure 5). The CTR for this page averages 4.3%, significantly higher compared to the 1% for the entire EuroGCT site.

We have also recorded a significantly longer retention time for these EuroGCT original resource pages. For the 'Packaging and Labelling' and 'Manufacturing authorisation' and page, the average retention time is 4:10 and 4:13 minutes (see Figure 4), respectively. This is 2.5 times longer than the averaged 1:41 minutes for the entire site, indicating users are really reading and learning from these resources we created and published.

uroGCT •					Feb 1, 2022 to Jul 15	, 2023
h is 'rresearch-pathways/manufacturing/manufacturing authoris $1 \qquad 277$	ation" ⊙ Clear 401 •	filters	04:13	84% •	0	
Visitors +277	Views +401		Avg time on site +	04:13 Bounce rate +84%	Event completions	
oomains Pages	Entries	Visitors	Views	Referrers Refs	Visitors	View
urogct.org/research-pathways/manufacturing/manufacturing- uthorisation	277	316	401	Google Direct / Unknown	256	29
				Bing	6	e
				DuckDuckGo	3	
				Yahoo	2	
				Yandex	1	



Figure 4. Webpage stats for the 'Manufacturing Authorisation' page. Main referrers is Google. Average time on site is 4:13 minutes. Record in Fathom Analytics between website launch and 15 July 2023.

QUERIES	PAGES	COUNTRIES	DEVICES	SEARCH APPEARAM	VCE.	DATES	
							Ŧ
Top pages				↓ Clicks	Impressions	CTR	Positio
https://www.eurogct.org/research-pathways/r	manufacturing/manufacturing-autho	risation		286	6,640	4.3%	19.
					Rows per page: 10	♥ 1-1 of 1	< >
QUERIES	PAGES	COUNTRIES	DEVICES	SEARCH APPEARAN	ICE	DATES	
							7
Top queries				↓ Clicks	Impressions	CTR	Positio
manufacturing authorization				25	243	10.3%	3
manufacturing authorisation				20	227	8.8%	3
manufacturing authorisation holder				6	84	7.1%	3
manufacturing authorization holder				4	128	3.1%	7.
manufacturers authorisation				3	75	4%	2
manufacturing authority				1	88	1.1%	18
manufacturing authorization certificate				1	9	11.1%	7.

Figure 5. Webpage stats (top) for 'Manufacturing Authorisation' page and the list of top query terms (bottom). Recorded by Google console between website launch and 15 July 2023.

In D2.4, we have reported our observation on a distinct user profile for WP3 and WP4 content. Here we report that the indicators that reflect information uptake vary depending on the nature of the webpage: for directory search pages, the total views to visitor ratio tends to be higher and bounce rate is significantly lower; for individual resource pages the ratio is closer to 1:1 with a bounce rate representative of the site's bounce rate; topical pages sit in between the two types. We have also recorded the significantly longer user retention time for original resources produced by the EuroGCT consortium. We will continue to monitor website information uptake, and use these data to shape future reporting metrics and audience engagement strategies.

Research Pathways has a worldwide reach. Figure 6 shows that the Research Pathways pages have been accessed by users from countries beyond EU and UK. These countries include the US, Taiwan, India and China. This demonstrates that while the information regarding medicine legislation, regulation, and access is EU-specific, other Research Pathways resources have been utilised by communities outside of our target audience and can be useful irrespective of their geographical location.

Countries	Visitors
United Kingdom	74
France	39
United States of America	16
Taiwan, Republic of China	9
Luxembourg	7



Germany	5
Spain	4
Ireland	4
India	4
China	3

Figure 6. 'Research Pathways' page accesses listed by country recorded by Fathom analytics between website launch and 15 July

4. Conclusion and future work

Activities on disseminating WP4 outputs include establishing and updating the EuroGCT website, event attendance, presentations (both online and in-person), posters, and networking activities. The Research Pathways section, the output of WP4, contains information mainly targeted toward experts. We have mainly focussed on in-person and online events that allows direct interaction with these WP4 target audiences. Our direct engagement at meetings and networking events is effective and has resulted in a number of inquiries, collaborations in discussion and formed.

Complementary to direct engagement, the establishment of the EuroGCT online research and regulatory community hub, Research Pathways, has broadened our dissemination actions and made this work accessible to audience in the EU, UK, and worldwide. It also serves audiences beyond our targeted expert audience groups, giving an impact that will be beyond traditional academic publishing. We anticipate the improved search-ability and usability in the Research Pathways will greatly enhance user's experience and their learning when reading the resources within the section. The new content type 'Case Studies' could attract interest and opportunities for collaboration, from both inside and outside of the consortium.

As for website traffic, reporting merely on the absolute visitor count is not suitable for evaluating the information uptake among the expert groups we are targeting. We need additional means and metrics including but not limited to, the user retention time, bounce rate, and the views to visitor ratio to reflect the information uptake. We will continue to monitor and evaluate these metrics, then use this information to feed into future reporting as well as to shape our audience engagement strategies.

5. List of Annexes

Annex 1. Abstracts and posters list from February 2022 to July 2023



EuroGCT

Annex 1. to Deliverable D.2.2

Abstracts and posters list from February 2022 to July 2023

Abstracts for the European Society for Gene & Cell Therapy Congress 2022 11-14 October 2022, Edinburgh, the UK <u>https://www.esgctcongress.com/</u>

<u>Title:</u> Bringing gene and cell therapies from lab to patients: the EuroGCT research pathways

Auxane Delage,¹ Luc-Sylvain Gilbert,² Hsin-Yu Kuo,³ Jennifer Lorigan,⁴ Clare Blackburn,⁵ Anna Couturier,⁶ Amanda Waite,⁷ Aurélie Mahalatchimy⁸

Bringing gene and cell therapies from lab to patients raises many challenges from the development of these therapies to patient access. Therapy development has to comply with many regulatory requirements, some being binding, other being guidance only, in order to primarily ensure patients' safety. These requirements have been established throughout the life cycle of these therapies from fundamental research to post-administration vigilance, through manufacturing, clinical trials, marketing authorisation, patentability, or pricing & reimbursement. While the majority are governed by European Union law, several aspects remain regulated at national levels. The legal classification of these therapies also leads to different regulatory pathways. Therefore, their development is not only complex scientifically, it is also complex regarding their regulatory landscape, which is made up of a combination of general and specific rules and guidance depending on competent institutions (e.g. EU and Member States regulatory agencies or health technology assessment bodies), types of products, and steps of their developments. To address this complexity, the European Consortium for Communicating Gene and Cell Therapy Information (EuroGCT), is building an online tool to provide research pathways' information, that will be presented in this poster, to facilitate better decision-making at key points in development of new therapies and thus

¹ EuroGCT Information Officer on Ethical, Legal & Societal issues, Research Engineer and PhD student in law, Law Faculty, UMR 7318 International, Comparative and European laws, UMR 7318 DICE CERIC, CNRS, Aix Marseille University, Toulon University, Aix-en-Provence, France.

² EuroGCT Information Officer on Ethical, Legal & Societal issues, Research Engineer in law, Law Faculty, UMR 7318 International, Comparative and European laws, UMR 7318 DICE CERIC, CNRS, Aix Marseille University, Toulon University, Aix-en-Provence, France.

³ EuroGCT Information Officer on ATMP Product Development Pathway, Centre for Regenerative Medicine, Institute for Regeneration and Repair, The University of Edinburgh, UK.

⁴ EuroGCT Information Officer on Gene and Cell Therapy, Centre for Regenerative Medicine, Institute for Regeneration and Repair, The University of Edinburgh, UK.

⁵ EuroGCT Project Coordinator, Centre for Regenerative Medicine, Institute for Regeneration and Repair, The University of Edinburgh, UK.

⁶ EuroGCT Project Manager – Digital and Technical, Centre for Regenerative Medicine, Institute for Regeneration and Repair, The University of Edinburgh, UK.


⁷ EuroGCT Project Manager – Information and Networks, Centre for Regenerative Medicine, Institute for Regeneration and Repair, The University of Edinburgh, UK.

⁸ EuroGCT Deputy coordinator and WP4 leader Permanent, Researcher in law at the French National Centre for Scientific Research (CNRS, chargée de recherche), Law Faculty, UMR 7318 International, Comparative and European laws, UMR 7318 DICE CERIC, CNRS, Aix Marseille University, Toulon University, Aix-en-Provence, France.

Abstract published in Human Gene Therapy, Volume: 33, Issue 23-24: December 14, 2022, A1-A212. http://doi.org/10.1089/hum.2022.29225.abstracts



Poster submitted to the European Society for Gene & Cell Therapy Congress 2022 11-14 October 2022, Edinburgh, UK





Abstract submitted to the 49th Annual Meeting of the EBMT, 23-26 April 2023, Paris, France

FINDING OUT THE REGULATORY REQUIREMENTS FOR THE DEVELOPMENT OF GENE AND CELL THERAPY PRODUCTS WITH THE EUROGCT RESEARCH PATHWAYS

A. Delage¹, L.-S. Gilbert¹, H.-Y. Kuo², J. Lorigan², C. Blackburn², A. Couturier², A. Waite², A. Mahalatchimy^{1,3}

¹Aix-Marseille University, Aix-en-Provence, France, ²The University of Edinburgh, Edinburgh, United Kingdom, ³CNRS, Aix-en-Provence, France **Preferred Presentation Type**: Poster

Topic: 31: Data Management

Title: FINDING OUT THE REGULATORY REQUIREMENTS FOR THE DEVELOPMENT OF GENE AND CELL THERAPY PRODUCTS WITH THE EUROGCT RESEARCH PATHWAYS

Background: Communicating information on the regulatory framework applicable to gene and cell therapies, at every stage of development and towards every actor involved, is a challenge. Therapy development needs to comply with several regulatory requirements mostly to ensure products' and patients' safety, the complexity comes from the diversity of the regulatory frameworks. Some requirements are binding, others are guidance only. Most aspects are governed by European Union law, but some remain regulated on a national scale. The regulatory landscape is a combination of general and specific rules and guidances depending on competent institutions (e.g. EU and Member States regulatory agencies or health technology assessment bodies), types of products, and steps of their developments.

Methods: The European Consortium for Communicating Gene and Cell Therapy Information (EuroGCT) is building an online tool to provide research

pathways' information. Therefore, communicating clear, precise, and accurate information in the form of a database. It will allow professionals of the field as well as patients to be informed on all regulatory aspects of the development of a Gene and Cell therapy product.

Results: Depending on the legal classification of these therapies different regulatory pathways appear, which are shown on the EuroGCT website. Becoming a "one-stop shop" for accurate legal information on the legal classification of Gene and Cell therapies from lab to patient.

Conclusions: The tool will facilitate better decision-making at key points in development of new therapies and thus enable improved product development, by providing the research community and regulatory and healthcare authorities with an information source on the practical steps needed for cell and gene therapy development.

Disclosure: Nothing to declare.

1. I confirm that the abstract and that all information is correct: Yes

2. I confirm that submission of the abstract constitutes consent to publication: Yes


3. I confirm that I submit this abstract on behalf of all authors. Yes

4. I confirm that all contributors have provided original material: Yes 5. I understand that the Annual Meeting and the publisher reserve the right to decline publication for any reason: Yes

6. Has this abstract been previously published online or in other media (journals, other meetings)? No



Poster submitted to the 49th Annual Meeting of the EBMT, 23-26 April 2023, Paris, France





Abstract submitted to the International Society for Cell & Gene Therapy 2023 Annual meeting, May 31-June 3, Paris, France

CONTROL ID: 3893338

TITLE: The Marketing Authorisation Of Advanced Therapy Medicinal Products Under The Regulation Of The European Union

AUTHORS (FIRST NAME, LAST NAME): <u>Aurélie Mahalatchimy</u>^{1, 2}, Luc-Sylvain Gilbert^{1, 3}, Auxane Delage^{1, 3}, Olivier Nègre^{4, 5, 6}

INSTITUTIONS (ALL): 1. UMR 7318 DICE CERIC, Aix-Marseille University, Centre National de la Recherche Scientifique, Marseille, Provence-Alpes-Côte d'Azu, France.

2. EuroGCT Deputy coordinator and WP4 leader, Aix-en-Provence, France.

- 3. EuroGCT Information Officer on Ethical, Legal & Societal issues, Aix-en-Provence, France.
- 4. EuroGCT Member of The General Committee Management Group, WP4 Co-Leader,, Paris, France.
- 5. Board Member of the French Society of Cell and Gene Therapy (SFTCG), Paris, France.

6. Expert in Cell and Gene Therapy at Biotherapy Partners, Paris, France.

ABSTRACT BODY:

Background & Aim: Advanced Therapy Medicinal Products (ATMPs) is a European classification of medicinal products based on genes, cells and tissues specifically regulated in the European Union (EU) from the entry into force of Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on ATMPs.

Any company wishing to market ATMPs within the EU must hold a Marketing Authorisation (MA) issued by the European Commission under the "centralised procedure", after a single application to the European Medicines Agency (EMA) and its scientific assessment by the Committee for Advanced Therapies. The purpose of the MA is to ensure high quality, safety and efficacy for ATMPs, with a positive risk-benefit balance, to be commercialised. The MA is valid in the EU Member States, Iceland, Norway and Liechtenstein for a five-years period.

Methods, Results & Conclusion: From the adoption of the EU regulation, 24 ATMPs have been granted a marketing authorisation in the EU and the European Commission decision is pending for another one. There has been a clear increase in approvals from 2018, and most approved ATMPs are gene therapy medicinal products. Almost half of them benefited from expediting pathways or regulatory support schemes for

(innovative) medicines to be commercialised in the EU. Nevertheless, MA has been withdrawn or not renewed for 7 of them.

This poster will present the European regulatory requirements and pathways for ATMPs to obtain marketing authorisation, and discuss the challenges of their commercialisation.

This work has been supported by the European Union's Horizon 2020 research and innovation programme under grant agreement No 965241 and by ANR-funded I-BioLex project (ANR-20-CE26-0007-01).

Abstract published in Cytotherapy, Vol. 25, Issue 6, Supplement, S160-S161, Published in issue: May, 2023



Poster submitted to the International Society for Cell & Gene Therapy 2023, Annual meeting May 31-June 3, Paris, France

TV.	Faculté de de Science Aix Marseille	e Politique	CNTS	UNR 7318-			BIOLEX	ANR) <u>S</u> C	7		
Tł	ne ma	arke	eting au	ith	orisat	tion o	fAd	va	nced T	her	apy Medicinal	
	Pre	odu	cts und	er	the re	egula	tion	of	the Eu	rop	ean Union	
			Aurélie N	/aha	atchimy ¹ , Lu	c-Sylvain G	ilbert ² , Au	xane	Delage ³ , Olivie	er Nèare	4	
Aix Mo Toulor CERIC, C ciety o	rseille Univ, Toulon Univ, Aix-en-Prove NRS, Aix Marseille U I Cell and Gene The	Univ, Aix-en- nce, France, Iniv, Toulon U rapy (SFTCG	Provence, France, ² EuroGCT I EuroGCT Information Officer niv, Aix-en-Provence, France,), Chief Scientific Officer at Sr Innovatific	nformati on Ethic Biothe nart Imn	on Officer on ELSL Res- rt Legal & Societal iss apy Partners, Paris, Fr june, Co-President Ga	earch Engineer in lav ues (ELSI), Research rance, EuroGCT Mem sne and Cell Therapy resement No 965241	v, Law Faculty, U Engineer and Ph ber of The Gene Institute (G&CT	MR 7318 In D student ral Comm 1). Acknov	ternational, Comparativ in law, Law Faculty, UMI littee, Management Gro vledgments: This work h or project (ANP-20, CCP	ve and Europe R 7318 Internat up Deputy Co las been supplies 5=0007=01)	parative and European laws, UMR 7318 DICE CERIC, CNR an laws, UMR 7318 DICE CERIC, CNRS, Aix Marseille Univ, ional. Comparative and European laws, UMR 7318 DICE ardinator, WP4 Co-teader, Board Member of the French orted by the European Union's Horizon 2020 research an	
AC	KGROU	ND &	AIM									
urope ny ce	ean Union (El ompany wist	J) from th ning to n	he entry into force on narket ATMPs within	of Reg n the	ulation (EC) No EU must hold	a Marketing	the Europe Authorisati	ean Pa on (M/	rliament and of A) issued by the	the Coun e Europeo	and tissues specifically regulated in t incl of 13 November 2007 on ATMPs. In Commission under the "centralis	
nera	oies (CAT). Th	ne purpo	se of the MA is to er	nsure	high quality, so	afety and effic	acy for ATM	MPs, wi	th a positive risk	-benefit i	g notably the Committee for Advanc balance, to be commercialised.	
afety	of the ATMP	is insuffi	cient and if the risk	-bene	fit balance is i	not favourabl	e. Moreove	r, expe	diting MA pathy	ways and	ded or withdrawn if the quality and t regulatory tools have been develop	
Itern	ative to stand	dard CP		strict	conditions on	ly. This poster					cess ATMPs without MA. The latter c irements and pathways for patients	
	STAND				Continencialis	EMA		_				
			(c		aft opinion on		СНМР		Eur	opean	MA decision binding in all	
proce	nsive and tim ass which car	n delay p	atients'		y safety and cy of ATMPs	ree	commendo	ation		mission	Member states + EEA for 5 years	
	et access	lithough	widest	~					Acronyms CAT, CHMP, MA	EEA?		
			PROC	DU	RES AND	PROGRA		ORI	EARLIER AG	CCESS		
EVE		ADVET	ING AUTHORISA			'e			Y SUPPORT S	CHEME	TO ALLOW AN EARLIER ACCES	
LAI	Accelere	ated	Conditional MA		MA under Ex	ceptional	TO ATM		rity Medicines (Pl		IMP PILOT for academia and non-profit	
gal	Assessn Article 14(9) F		Article 14a Reg 726/2	2004	Circums Article 14(8) Reg		What		hanced interaction	on & En	ganisations hanced regulatory support for up to five	
asis	726/2004							devel	dialogue to optin opment plans &	de	lected ATMPs to optimise their evelopment.	
hat	Assessment 1 MA ≤ 150 day:	ment time for Less complete data for Inability to provide arlier authorisation comprehensive safety		safety &	P		ed- up evaluation of nising medicines					
				2	fficacy data for objective & erifiable reasons		Why		To support medicine development		To support translation of basic research into medicine	
hy ow	Major interes		Early acce Seriously debilitating		Rare condition or collection		Criteria How	Foste	ring early dialog		igh medical need uiding through the regulatory process	
	public health medical need	d)	life-threatening diseases, emergenc	y i	of full information of possible in t	he state of	is impre		igns			
	Standard MA	criteria	situations, orphan drugs, unmet medic needs		scientific knowle unethical	edge or	Who		tial candidate for ated person at EM	MA AT	ademic/Non-profit MP developers to national competent	
'no		MA A	Standard MA Criteria				When		f existing routes o	of Po	Ithority or EMA ssible to use existing support scheme	
hen	Before submi MA BUT shoul	ission of	Befo	an Medicines Agency efore submission of MA iscussed earlier via scientific advice /				Clinic	approval, especially AA Clinical stages of development		(e.g., PRIME) Early stages of development (from best practice principles for manufacturing to	
	discussed eo PRIME				assistance			(or ea	arlier for academi	ics pl	anning clinical developments)	
onym	s: Marketing Auth	orisation (N	1A), Accelerated Assessm						Medium Enterprises (ESS TO ATMP		Mediccines (PRIME)	
		Compo	issionate use: is of patients			Compassiona Named-patier	te use: Its basis			ATI	MP Hospital Exemption	
gal asis		A	rticle 83 tion 726/2004			Article 5 Directive 2001	1			R	Article 28.2 regulation 1394/2007	
hat	(life-threatenin	ng, long-la	seriously ill groups of p sting or seriously debili	tating	of an authoris	ed health-care			e used within the	e same Men	routine basis, specific quality standards, & nber State in a hospital under the exclusive	
hv			nical trials or MAA proce		by an individu				individual med	lical prescri		
ow	use programm	nes	ccess to compassionat itions & national rules	e	ongoing clinic		nts, including	without			ive ATMPs under controlled conditions ility & pharmacovigilance requirements and	
ho			tent authority to EMA &			nt to National co	npetent auth	nority	quality standar	rds equivale	ent to ATMPs going through the MA pathway o National competent authority	
ime		int to Natio	nal competent authori	42.0	МА Туре		Current status					
ondro ybera	Celect TEP	Orthopaedi Gastrology	;	2009	Standard Exceptional		Withdrawn, 29 Withdrawn, 28			EU supp	orts and fosters ATMPs' researc	
tCI ovenge	CTMP	Orthopaedie Oncology		2013	Standard Standard		Withdrawn, 1-7 Withdrawn, 6-1		patients acces	s to effec	ess to market with regulatory tool tive and affordable ATMP is limited b	
loclar lygic	GTMP	Ophthalmol Oncology		2015			Positive Positive		the high ave authorised AT	rage co MPs from	st per patient, the withdrawal of MA holder mostly for commercie	
rimveli Imoxis	GTMP CTMP	Graft vs. hos	st	2016 2016	Conditional		Positive Withdrawn, 9-	10-2019			ences between healthcare system tegies of the different Member States	
herox ofisel	TEP TEP	Orthopaedi Gastrology		2017 2018	Standard		Positive Positive					
scarta mriah	GTMP GTMP	Immunocel	ular cancer	2018 2018	Standard (PRIME) Standard (PRIME)		Positive Positive		pathways prov	ide the v	procedure and the expediting M videst commercialisation of ATMPs	
cturna nteglo	GTMP GTMP	Ophthalmol Beta-Thalas			Standard Conditional/Acceler	rated (PRIME)	Positive Withdrawn, 24	-3-2022	Europe, patien	nts' acce	ss to ATMPs is dependent on M holder strategy to make the produc	
gensn meldy		Muscular At		2020	Conditional/Acceler Accelerated		Positive Positive		available in Eur	rope. The	latter is linked to the agreement(s) a	
	GTMP	Lymphoma,	Mantle-Cell	2020	Conditional/Acceler		Positivo	11-2001			nent to provide affordable ATMPs o financial benefit, including return o	
/sona ecma	GTMP	Cancer of p		2021	Accelerated (PRIME) Conditional/Acceler	rated (PRIME)	Withdrawn, 18- Positive	-11-2021	investment, for			
	GTMP	Blood cance		2022 2022	Accelerated (PRIME) Exceptional)	Positive Positive		Patients can a		ss ATMPs, thanks to other pathway	
	GTMP		oma cancer of the bone marrow	2022	Conditional (PRIME)		Positive	_	alternative to	MA and j	possible under strict conditions onl	
əyanzi staza ırvykti	(2TMP		a A iferative Disorders	2022	Exceptional (PRIME)		Positive				<mark>how these o</mark> ther pathways can b	
eyanzi istaza irvykti ictavia vallo	CTMP								used according	a to the a	pplicable national heterogenous rule	
eyanzi staza irvykti ctavla vallo mgeni 25 aut	CTMP GTMP horised ATMPs in th	Haemophili e European		2023	Conditional (PRIME)		Positive	0	(e.g., hospital	exemption	pplicable national heterogenous rule on), they could also lead to unfo he high requirements for MA granting	

Most opproved a Mars all gene thereby interacting products.
 Half of authorised ATMPs benefited from expediting pathways or regulatory support schemes for (innovative) medicines
 BUT MA withdrawn or not renewed for 7 ATMPs.



Abstract submitted to the International Society for Cell & Gene Therapy 2023

Annual meeting, May 31-June 3, Paris, France

<u>Title</u>: Which actors to influence the adoption of EU guidelines for Advanced Therapy Medicinal Products?

Aurélie Mahalatchimy,¹ Valentin Brunel² - Abstract published in Cytotherapy Volume 25, Issue 6, Supplement, May 2023, Page S161

Genes, cells, and tissues based medicinal products are specifically regulated as Advanced Therapy Medicinal Products (ATMPs) within the European Union (EU) from the adoption of Regulation (EC) n°1394/2007 on ATMPs. Beyond legislative requirements, the complexity and scientific technicity of these medicines, as well as the necessary flexibility to take into account the evolutions and the scientific and regulatory experience gained has led to the development of an important amount of guidelines in the field.

These guidelines have mainly been adopted by the European Medicines Agency (EMA), the European regulatory agency especially in charge of the scientific assessment of medicines to be commercialized in the EU. Some of them have also been adopted by the European Commission which grants the final marketing authorization for medicines to enter the EU market.

The adoption of EU guidelines involves a public consultation procedure to gather comments from stakeholders and interested parties.

Our poster aims at mapping these different actors, and their potential changes over time, to allow for a realistic and concrete portrait of all stakeholders and interested parties involved in the field of ATMPs regarding their European regulation through guidelines.

The identification of EU scientific guidelines applicable to ATMPs, and of the actors involved in the consultation process has led to the establishment of a database with over 200 organizations corresponding to fourteen guidelines for which dates of production range from 2008 to 2022. The organizations have been classified by type (Business, Academia, National bodies, etc.), country, and theme of the drafts of guidelines they commented on. This poster especially highlights and discusses which organizations have influenced the adoption of EU scientific guidelines on ATMPs; some of them commenting almost all guidelines in the field while others considered only certain guidelines.

Findings concern both the number and quality of stakeholders with the aim to understand over time, what types of organizations from which country have been the most active in answering to guidelines' consultations, who were the major or more prolific respondents, and what themes were more often commented.

¹ EuroGCT Deputy coordinator and WP4 leader, Permanent Researcher in law at the French National Centre for Scientific Research (CNRS, chargée de recherche), Law Faculty, UMR 7318 International, Comparative and European laws (DICE) CERIC, CNRS, Aix Marseille University, Toulon University, Pau & Pays de l'Adour University, Aix-en-Provence, France.

² Research Engineer, CNRS, UMR 7318 International, Comparative and European laws (DICE) CERIC, CNRS, Aix Marseille University, Toulon University, Pau & Pays de l'Adour University, Aix-en-Provence, France



Poster submitted to the International Society for Cell & Gene Therapy 2023 Annual meeting, May 31-June 3, Paris, France

WHICH ACTORS TO INFLUENCE THE ADOPTION OF EU GUIDELINES FOR ADVANCED THERAPY MEDICINAL PRODUCTS?

Aurèlie Mahalatchimy: Permonent Researcher in law at the French National Centre for Scientific Research (CNRS, chargée de recherche), Law Faculty, UMR 738 i Ar Maesel Chin, Solan University, Pau & Pay de Frabar University, Anix-in-Province, France, Coordinator al Hoßkie project, Dapuy consolinator and MPA leader Valenta Brauch Keneer Singmer, CNRS, UMR 738 International, Comparitive and Europen Internation (CDIT (CERC, CNRS, Al Maeselle Link, Jackie University, Anix vs (DICE) CERIC, CNRS. 318 International, Comparative and European laws (DICE) ader of EuroGCT project. Pau & Pays de l'Adaur University, Aix-en-Provence, France

Results

Background and Methodology

Decay, cells during and cells the spectral products on specific cells regulated as duranced Theory Medicinal Products (MW) whith the Expense internet (E) from the despine of Tegulations (C) of TM2/2027 at MWs. Byood Byolichian regulaterents, the completion and cereficit behaviors and the despine of Tegulations (C) of TM2/2027 at MWs. Byood Byolichian regulaterents, the completion and cereficit behaviors and the completion of the completion and the com

ins to allogic identify the m

Main figures

Suidolino	Author	Thomo	Date	Number of orga
ion-clinical testing for inadvertent germline transmission of gene transfer vectors	EMA	GTMP	16/11/2006	4
invironmental risk assessments for medicinal products containing, or consisting of, genetically modified organisms (GMOs)	EMA	OMO MP	11/12/2006	4
tuman cell-based medicinal products	EMA	CT and TEP	21/05/2008	20
von-clinical studies required before first clinical use of gene therapy medicinal products	EMA	GTMP	50/05/2008	4
iclentific requirements for the environmental risk assessment of gene-therapy medicinal products	EMA	GTMP	50/05/2008	7
ollow-up of patients administered with gene therapy redicinal products	EMA	GTMP	22/10/2009	1
Suideline on the minimum quality and non-clinical data or certification of advanced therapy medicinal products	EMA	AIMPs	15/10/2010	6
Porency testing of cell-based immunotherapy medicinal products or the treatment of cancer	EMA	GIMP	21/07/2016	4
Buidelines on Good Manufacturing Practice specific to Advanced Inerapy Medicinal Products	EC	AIMPs	22/11/2017	55
Quality, preclinical and clinical aspects of gene therapy redicinal products	EMA	GTMP	22/05/2018	29
Suidelines on Good Clinical Practice specific to Advanced Therapy Medicinal Products	EC	AIMPs	10/10/2019	54
Quality, non-clinical and clinical aspects of medicinal products containing genetically modified cells	EMA	GMO MP	12/11/2020	20
Guideline on core SmPC, Labelling and Package Leaflet for advanced herapy medicinal products (AINPs) containing genetically modified cells	EMA	ATMPs	10/05/2022	9

 11/13 guidelines have been odopted from 2008.
 6/13 guidelines relate to GTMP. adopted from 2008. If //B guidelines have been established by EAA. GMO AM a constraint of the constrai Discussion


Iscussion There is a value scale of involvement in public consultation processes, ranging from only 1to 53 organisations having been involved. The number of organisations involved in public consultations processes is linked to the guidelines' topics and not to a potential increase due to better avareness of the process with time. Almost half of the guidelines' for which a report on public consultation is available, have been adapted in the field of CMW which häptights the sure of the type of AINPh their development and commercialisation in the EU. On the opposite, noting equideline consultation processes are the ones adapted by the EC. This can be explained

by both their highest legal value and the wider scope of their topic on particularly challenging agapets of ATMB development: Good Mann/acturing Practice and Good Clinical Practice specific to ATMPs. The other guidelines involving a bit processes organisations during the public consultation processes damages and the specific to ATMPs. The other guidelines involving a bit processes damages and a specific to ATMP and the specific to therapy medicinal products for CTA IEP (20), and Quality, non-clinical and clinical agapests of gene participation than for other types of products. Sudelines mumber of cognisations, even though only the first one covers two sub-categories of ATMPs explicitly defined (the seles, the level (Regulatorin (EC) n°15/42/2007 and Directive 2009/120/EC). The other guidelines involving less organizations (prosection they cover very particular scientific (e.g., potency testing) or regulatory (e.g., packaging procedure (e.g., certification).

Organisations' profile



Discussion: Companies and business associations account for almost half of all contributions (47%). Community organisations (5%) and individuals (2%), on the contrary, seldom contribute, As for public sector organisations, such antional badies and academic institutions, likely hold the middle ground (24%). These results can be explained by the availability of means [luman and financial ones in particular regarding necessary time and knowledge) to contribute to the process of public consultation.



Most contributing organisations

Organisation

Number of contributions	Organisations	- 50	4/9 are located in Belgium.
Three or more	9		4/9 are Business Associations
Two	23		5/9 are from the private sector (Company or Business Association).
One	115		2/9 are Networks/Innovation Organisations.

inscruptures intere. The important involvement of the UK (24%) can be explained by the UK being one of the leading countries in the field, although almost all public consultations processes considered (12/15) occurred before Brexit. Thus, such main position of the UK may change in the future. The important involvement of the USA (14%) can be actionshing given that the public consultations relate to European regulation. However, it reveals how much the field is International and how much the European Mathetis is torgeted by external countings, especially the USA.

Discussion

As long as only few organisations have contributed to 2 and to 5 or more consultations, and 78,2%, of organisations contribute only once to a consultation process on ATMPs guidelines, it appears the contribution are based on the topics of the guidelines rather than on an habit to be involved in this process.

In this process. Arrong organisations contributing most often, the private sector is leader given the means it can dedicate to this activity; and Belgium is the most represented country given the strategical position of being in Brussels to frave and influence EU policy and regulation. Surprivingly, the public sector, mainly expresented by National bodies and cacdowing: (research institution, does not appear among the organisations contributing the most often to public consultation regarding AIMPs guidelines timplies a participation based on the topics of the guidelines rather than on habit. Although this can be understood for academic/ research institution which generally facus on specific area of research were in the delinet of field AIMP; it is many sustainable for national badies, and expectiony national authorities, such as national medicines agencies, which could have been considered as the main contract point for AIMP developers, despite non EAMA compositions, given national languages and their potential interface's role between the EMA and AIMP's developers located in National EU Member States.

ety for Cell & Gone That eutical Industry Associat **General conclusion**

- Most guidelines have been adopted after the adoption of Regulation (EC) n°1394/2007 on 13 November 2007 and have contributed to its practical implementation. U and have contributed to its protocial implementation. It guidelines applicable to ATMPs have been established by the EMA. It highlights both the main role the agency in this field and the technical specificity of ATMPs. Guidelines on Goad Manufacturing totlee and on Goad Clinical Practice specific to ATMPs have been adopted by the EC in accordance In the provisions of Regulation (EC) n°1594/2007. ing .

- with the provisions of Regulation (EC) n⁴1394/2007. More EMA guidelines but more contributions on EC guidelines due to highest legal value and wider scope of him trapic on princilarly challenging aspects of AIMPs. development A wide scale of involvement in the public consultation processes: from 1 to 55 organisations The more general a guideline is, the more contributions it obtations Involvement in the public consultations processes is linked to the guidelines' topics, and neither to a potential increase due to better awareness of the process on time nor to an habit to contribute even for national regulators.
- Aix*Marseille universite Socialement engagée



USA UK Belgium Belgium Canada

GTMP is the category of ATMPs raising the most of interest The private sector is leader in answering public consultation on ATMPs guidelines, both regarding the overall amount of contributions and the organisations that contributed the most offen. The countries most represented are the UK, Belgium, USA, France, Germany, Italy and the Netherlands The major involvement of the UK may change in the future following Breat.

The important involvement of the USA reveals how much the field lasternational and how much the European Market is targeted by external countries, especially the USA. The important involvement of Belgium should be put in perspective with the European institutions being mainly established in Brussels which leads to an important amount of organisations having their headquarters there and to organisations that may be more used to EU policy and regulation (Belgium is the most represented country among the organisations contributing most often).









Abstracts submitted to the European Society of Gene & Cell Therapy 24-27 October 2023, Brussels, Belgium

Title : The challenges of Advanced Therapy Medicinal Products manufacturing in the European Union: Strengths and limits of current regulatory tools

Luc-Sylvain Gilbert,³ Auxane Delage,⁴ Aurélie Mahalatchimy,⁵

Advanced Therapy Medicinal Products (ATMPs) is a European classification of medicinal products based on genes, cells and tissues specifically regulated in the European Union (EU) from 2007.

Any company wishing to manufacture ATMPs in the EU must hold a manufacturing authorisation issued by the national competent authority of the Member State where they carry out these activities.

Ensuring the quality of medicines is a criterion to obtain ATMPs' marketing authorisation issued by the European Commission under the "centralised procedure" after a single application to the European Medicines Agency. All ATMPs marketed in the EU must be produced in accordance with EU quality standards to ensure the quality, safety and efficacy of medicines for the patients: Good Manufacturing Practice (GMP) principles and guidelines dedicated to ATMPs enforceable since 2017, and relevant parts of the European Pharmacopeia provide the main regulatory standards to comply with.

The manufacture, meeting the GMP requirements from the raw materials to the final product, is particularly challenging for ATMPs regarding their level of complexity and their specific characteristics, especially the use of substances of human origin as starting materials, and the reproducibility when using live biological samples. The ATMPs' manufacturer has to maintain costly technical specifications capable of guaranteeing the reproducibility of the medicine's composition in accordance with GMP guidelines and the specific requirements of the ATMP marketing authorisation.

Regulatory requirements are often seen as obstacles to the development of ATMPs. Nevertheless, they mainly provide a set of solutions to overpass the technical obstacles of ATMPs' manufacturing in order to ensure their quality for the safety of patients. It appears clearly within the various supporting regulatory tools currently available at the European level, which include both guidance documents and procedures for interactions with regulators.

This poster will provide an overview of the challenges of ATMPs' manufacturing and link them to the relevant supporting regulatory tools highlighting both their strengths and their limits in the context of ATMPs development for patients.

This work has been supported by the European Union's Horizon 2020 research and innovation programme under grant agreement No 965241 and by ANR-funded I-BioLex project (ANR-20-CE26-0007-01).

³ EuroGCT Information Officer on Ethical, Legal & Societal issues, Research Engineer in law, Law Faculty, UMR 7318 International, Comparative and European laws (DICE) CERIC, CNRS, Aix Marseille University, Toulon University, Pau & Pays de l'Adour University, Aix-en-Provence, France.

⁴ EuroGCT Information Officer on Ethical, Legal & Societal issues, Research Engineer and PhD student in law, Law Faculty, UMR 7318 International, Comparative and European laws (DICE) CERIC, CNRS, Aix Marseille University, Toulon University, Pau & Pays de l'Adour University, Aix-en-Provence, France.

⁵ EuroGCT Deputy coordinator and WP4 leader Permanent, Researcher in law at the French National Centre for Scientific Research (CNRS, chargée de recherche), Law Faculty, UMR 7318 International, Comparative and European laws (DICE) CERIC, CNRS, Aix Marseille University, Toulon University, Pau & Pays de l'Adour University, Aix-en-Provence, France.



Title: Mapping regulators' early interactions procedures to support innovation

Auxane Delage⁶, Luc-Sylvain Gilbert,⁷ Aurélie Mahalatchimy⁸

In an effort to help stakeholders to overcome the legal and scientific challenges raised during the development of a medicinal product, procedures, such as scientific advice, have been established in the European Union to enable early contact with regulators, especially in the field of gene and cell therapy. These procedures help to support innovation. They are various: some are available for all medicines and others target innovative medicines or Advanced Therapy Medicinal Products (ATMPs); some are legislative or regulatory schemes, others put into place services; some benefit to all types of medicines' developer, others target a specific type of developer. These procedures for early interactions between stakeholders and regulators are available to facilitate communication between institutions and medicine developers all along the medicine's lifecycle, but the main focus is on the pre-marketing authorisation phase. The exchanges occurring between regulators and the seeker of interaction can impact the chances an ATMP has to enter on the market. Thus, the aim is to foster their development by helping developers to navigate the regulatory pathways adequately for ATMPs to meet quality, safety, and efficacy requirements according to robust evidence to obtain marketing authorisation and access to patients. Knowing all the procedures, who can ask for them, which procedure to use, and with which regulator can be a challenge. Moreover, the extent of the possible support is often overlooked.

This poster describes and discusses the multiple existing options available to ATMPs' developers to overcome challenges during the pre-marketing authorisation phase through early interactions with regulators, here focusing on the European Medicines Agency and National agencies. Communicating on the early procedures available at national and European levels will help to identify potential gaps and raise developers' awareness of the different procedures available to support the marketing authorisation of ATMPs.

⁶ EuroGCT Information Officer on Ethical, Legal & Societal issues, Research Engineer and PhD student in law, Law Faculty, UMR 7318 International, Comparative and European laws (DICE) CERIC, CNRS, Aix Marseille University, Toulon University, Pau & Pays de l'Adour University, Aix-en-Provence, France.

⁷ EuroGCT Information Officer on Ethical, Legal & Societal issues, Research Engineer in law, Law Faculty, UMR 7318 International, Comparative and European laws, UMR 7318 DICE CERIC, CNRS, Aix Marseille University, Toulon University, Aix-en-Provence, France.

⁸ EuroGCT Deputy coordinator and WP4 leader Permanent, Researcher in law at the French National Centre for Scientific Research (CNRS, chargée de recherche), Law Faculty, UMR 7318 International, Comparative and European laws, UMR 7318 DICE CERIC, CNRS, Aix Marseille University, Toulon University, Aix-en-Provence, France.



Poster submitted to the 2022 International Mammalian Synthetic Biology Workshop (mSBW), 28-29 July 2022, Edinburgh, UK

Communicating **reliable** and **accessible** information about **gene and cell therapy**



THE UNIVERSITY of EDINBURGH Institute for Regeneration and Repair

Centre for Regenerative Medicine

Clare Blackburn, Jennifer Lorigan, Amanda Waite, Anna Couturier, Hsin-Yu Kuo¹ 1. Centre for Regenerative Medicine, Institute for Regeneration and Repair, The University of Edinburgh, UK.



About the Project

The European Consortium for Communicating Gene and Cell Therapy Information (EuroGCT) is a European Union funded project led by the University of Edinburgh. The consortium unites 47 partner organisations and institutions across Europe, including the major European advanced therapies learned societies, with the common goal of providing reliable and accessible information related to cell and gene therapy development to European stakeholders.

EuroGCT brings together wide-ranging expertise, including **basic** and **clinical research**; **ATMP development**; **ethical**, **legal** and **societal impacts**; and **public engagement**.

We link with target audience representatives. These include people affected by conditions, educators, healthcare professionals, regulators, policymakers, and the media.

EuroGCT has established infrastructure for:

- · Coordinated approach to communication
- Collaborative resource development
- Increased reach and impact
- · Building capacity in the scientific community
- · Evaluation and sharing of best practice

Objectives

- Our aim is to support better informed decision-making related to cell- and gene-based therapies for researchers and the public.
- We provide **patients**, **people affected by conditions**, **healthcare professionals** and **citizens** with accurate scientific, legal, ethical and societal information and engagement opportunities.
- We provide the **research community**, **regulatory** and **healthcare authorities** with an information source on the practical steps needed for cell and gene therapy development for the purpose of facilitating better decisionmaking at key points in development of new therapies and, thus, enable improved product development.

Get Involved

We need...

- Your expertise. Communicate your research to a wide audience and help ensure the accuracy of our content by participating in our Network of Expertise.
- Your skills. Contribute to the accessibility of our information by writing, reviewing or translating content.
- Your content. Share your public- or patientfacing resources or your research news.
- Your network. Tell other researchers and target audience members about the website and the project.

Email: j.lorigan@ed.ac.uk

www.eurogct.org

* * * * * * * * *

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 965241